Pharming Group N.V. announces publication of its Annual Report for the financial year ended 31 December 2018. The Company also announces that it has made a provisional commitment to invest up to €1.6 million in cash and convert €2.5 million of prepayments into equity in its fill & finish partner BioConnection BV, which manufactures the final sealed vials of Pharming’s product RUCONEST® from the purified drug substance.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2018.

Pharming Webinar: Jaarcijfers 2018 donderdag 7 maart 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!

Pharming Group N.V. announced today that an abstract was presented this week at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, CA. Additionally, Pharming is pleased to announce sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAAI Lectureship.

Pharming Group N.V. today announces that two abstracts were presented at The Western Society of Allergy, Asthma & Immunology (WSAAI) in Maui, Hawaii, USA on January 22-24, 2019.

Pharming Group N.V. today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).

In deze webinar wordt Pharming Group CEO Sijmen de Vries geïnterviewd door Lifespring’s Leon Melens over de recente Investor tour die Pharming organiseerde in 2018, de positieve studieresultaten van eerste door onderzoekers geïnitieerde studie met rhC1INH in contrast-geïnduceerde nefropathie (nierschade door gebruik van contrastvloeistof) en de financiële resultaten van het derde kwartaal.

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.

Pharming Group N.V. announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.

Pharming Group N.V. announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the supplemental Biologics License Application (sBLA) for RUCONEST® [C1 Esterase Inhibitor (recombinant)] to expand the current indication to include prophylaxis in patients with hereditary angioedema (HAE).